B-intervention	0	9	Pegylated
I-intervention	10	19	liposomal
I-intervention	20	31	doxorubicin
I-intervention	32	36	plus
I-intervention	37	46	docetaxel
O	47	60	significantly
O	61	69	improves
O	70	74	time
O	75	77	to
O	78	89	progression
O	90	97	without
O	98	106	additive
O	107	121	cardiotoxicity
O	122	130	compared
O	131	135	with
O	136	145	docetaxel
O	146	157	monotherapy
O	158	160	in
O	161	169	patients
O	170	174	with
O	175	183	advanced
O	184	190	breast
O	191	197	cancer
O	198	208	previously
O	209	216	treated
O	217	221	with
O	222	233	neoadjuvant
O	233	234	-
O	234	242	adjuvant
O	243	256	anthracycline
O	257	264	therapy
O	264	265	:
O	266	273	results
O	274	278	from
O	279	280	a
O	281	291	randomized
O	292	297	phase
O	298	301	III
O	302	307	study
O	307	308	.

O	309	311	To
O	312	321	determine
O	322	329	whether
O	330	333	the
O	334	345	combination
O	346	348	of
O	349	358	pegylated
O	359	368	liposomal
O	369	380	doxorubicin
O	381	382	(
O	382	385	PLD
O	385	386	)
O	387	390	and
O	391	400	docetaxel
O	401	414	significantly
O	415	423	prolongs
O	424	428	time
O	429	431	to
O	432	439	disease
O	440	451	progression
O	452	460	compared
O	461	465	with
O	466	475	docetaxel
O	476	481	alone
O	482	489	without
O	490	492	an
O	493	501	increase
O	502	504	in
O	505	512	cardiac
O	513	521	toxicity
O	522	524	in
O	525	530	women
O	531	535	with
O	536	544	advanced
O	545	551	breast
O	552	558	cancer
O	559	562	who
O	563	566	had
O	567	578	experienced
O	579	586	relapse
O	587	589	at
O	590	595	least
O	596	597	1
O	598	602	year
O	603	608	after
O	609	614	prior
O	615	623	adjuvant
O	624	626	or
O	627	638	neoadjuvant
O	639	652	anthracycline
O	653	660	therapy
O	660	661	.

O	662	666	This
O	667	680	international
O	680	681	,
O	682	687	phase
O	688	691	III
O	692	697	study
O	698	706	randomly
O	707	715	assigned
B-total-participants	716	719	751
O	720	728	patients
O	729	731	to
O	732	739	receive
O	740	746	either
B-control	747	756	docetaxel
O	757	759	75
O	760	762	mg
O	762	763	/
O	763	764	m
O	764	765	(
O	765	766	2
O	766	767	)
O	768	769	(
O	769	770	n
O	771	772	=
B-control-participants	773	776	373
O	776	777	)
O	778	780	or
O	781	784	PLD
O	785	787	30
O	788	790	mg
O	790	791	/
O	791	792	m
O	792	793	(
O	793	794	2
O	794	795	)
O	796	804	followed
O	805	807	by
O	808	817	docetaxel
O	818	820	60
O	821	823	mg
O	823	824	/
O	824	825	m
O	825	826	(
O	826	827	2
O	827	828	)
O	829	834	every
O	835	837	21
O	838	842	days
O	843	844	(
O	844	845	n
O	846	847	=
B-intervention-participants	848	851	378
O	851	852	)
O	853	856	and
O	857	866	continued
O	867	872	until
O	873	880	disease
O	881	892	progression
O	893	895	or
O	896	907	prohibitive
O	908	916	toxicity
O	916	917	.

O	918	921	The
O	922	929	primary
O	930	933	end
O	934	939	point
O	940	943	was
B-outcome-Measure	944	948	time
I-outcome-Measure	949	951	to
I-outcome-Measure	952	963	progression
I-outcome-Measure	964	965	(
I-outcome-Measure	965	968	TTP
I-outcome-Measure	968	969	)
O	969	970	.

O	971	980	Secondary
O	981	984	end
O	985	991	points
O	992	996	were
B-outcome-Measure	997	1004	overall
I-outcome-Measure	1005	1013	survival
I-outcome-Measure	1014	1015	(
I-outcome-Measure	1015	1017	OS
I-outcome-Measure	1017	1018	)
O	1018	1019	,
B-outcome-Measure	1020	1029	objective
I-outcome-Measure	1030	1038	response
I-outcome-Measure	1039	1043	rate
I-outcome-Measure	1044	1045	(
I-outcome-Measure	1045	1048	ORR
I-outcome-Measure	1048	1049	)
O	1049	1050	,
B-outcome-Measure	1051	1058	cardiac
I-outcome-Measure	1059	1067	toxicity
O	1067	1068	,
O	1069	1072	and
B-outcome-Measure	1073	1079	safety
O	1079	1080	.

O	1081	1090	Treatment
O	1091	1095	with
O	1096	1099	PLD
O	1099	1100	-
O	1100	1109	docetaxel
O	1110	1123	significantly
O	1124	1132	improved
B-outcome	1133	1139	median
I-outcome	1140	1143	TTP
O	1144	1148	from
B-cv-cont-median	1149	1150	7
I-cv-cont-median	1150	1151	.
I-cv-cont-median	1151	1152	0
O	1153	1155	to
B-iv-cont-median	1156	1157	9
I-iv-cont-median	1157	1158	.
I-iv-cont-median	1158	1159	8
I-iv-cont-median	1160	1166	months
O	1167	1168	(
O	1168	1174	hazard
O	1175	1180	ratio
O	1181	1182	[
O	1182	1184	HR
O	1184	1185	]
O	1186	1187	=
O	1188	1189	0
O	1189	1190	.
O	1190	1192	65
O	1192	1193	;
O	1194	1196	95
O	1196	1197	%
O	1198	1200	CI
O	1200	1201	,
O	1202	1203	0
O	1203	1204	.
O	1204	1206	55
O	1207	1209	to
O	1210	1211	0
O	1211	1212	.
O	1212	1214	77
O	1214	1215	;
O	1216	1217	P
O	1218	1219	=
O	1220	1221	.
O	1221	1227	000001
O	1227	1228	)
O	1229	1232	and
O	1233	1236	the
B-outcome	1237	1240	ORR
O	1241	1245	from
B-cv-bin-percent	1246	1248	26
I-cv-bin-percent	1248	1249	%
O	1250	1252	to
B-iv-bin-percent	1253	1255	35
I-iv-bin-percent	1255	1256	%
O	1257	1258	(
O	1258	1259	P
O	1260	1261	=
O	1262	1263	.
O	1263	1267	0085
O	1267	1268	)
O	1268	1269	.

B-outcome	1270	1272	OS
O	1273	1276	was
O	1277	1284	similar
O	1285	1292	between
O	1293	1296	the
O	1297	1300	two
O	1301	1307	groups
O	1308	1309	(
O	1309	1311	HR
O	1312	1313	=
O	1314	1315	1
O	1315	1316	.
O	1316	1318	02
O	1318	1319	;
O	1320	1322	95
O	1322	1323	%
O	1324	1326	CI
O	1326	1327	,
O	1328	1329	0
O	1329	1330	.
O	1330	1332	86
O	1333	1335	to
O	1336	1337	1
O	1337	1338	.
O	1338	1340	22
O	1340	1341	)
O	1341	1342	.

O	1343	1346	The
O	1347	1356	incidence
O	1357	1359	of
B-outcome	1360	1365	grade
I-outcome	1366	1367	3
I-outcome	1368	1370	or
I-outcome	1371	1372	4
I-outcome	1373	1380	adverse
I-outcome	1381	1387	events
O	1388	1392	were
O	1393	1400	similar
O	1401	1402	(
B-iv-bin-percent	1402	1404	78
I-iv-bin-percent	1404	1405	%
O	1406	1407	v
B-cv-bin-percent	1408	1410	72
I-cv-bin-percent	1410	1411	%
O	1411	1412	)
O	1412	1413	,
O	1414	1422	although
O	1423	1424	a
O	1425	1431	higher
O	1432	1441	incidence
O	1442	1444	of
B-outcome	1445	1449	hand
I-outcome	1449	1450	-
I-outcome	1450	1454	foot
I-outcome	1455	1463	syndrome
O	1464	1465	(
B-iv-bin-percent	1465	1467	24
I-iv-bin-percent	1467	1468	%
O	1469	1470	v
B-cv-bin-percent	1471	1472	0
I-cv-bin-percent	1472	1473	%
O	1473	1474	)
O	1475	1478	and
B-outcome	1479	1488	mucositis
I-outcome	1488	1489	/
I-outcome	1489	1499	stomatitis
O	1500	1501	(
B-iv-bin-percent	1501	1503	12
I-iv-bin-percent	1503	1504	%
O	1505	1506	v
B-cv-bin-percent	1507	1508	1
I-cv-bin-percent	1508	1509	%
O	1509	1510	)
O	1511	1515	were
O	1516	1524	observed
O	1525	1527	in
O	1528	1531	the
O	1532	1535	PLD
O	1535	1536	-
O	1536	1545	docetaxel
O	1546	1557	combination
O	1557	1558	.

O	1559	1567	Protocol
O	1567	1568	-
O	1568	1575	defined
B-outcome	1576	1580	left
I-outcome	1581	1592	ventricular
I-outcome	1593	1601	ejection
I-outcome	1602	1610	fraction
I-outcome	1611	1620	decreases
I-outcome	1621	1624	and
I-outcome	1625	1635	congestive
I-outcome	1636	1641	heart
I-outcome	1642	1649	failure
O	1650	1654	were
O	1655	1663	reported
O	1664	1666	in
B-iv-bin-percent	1667	1668	5
I-iv-bin-percent	1668	1669	%
O	1670	1673	and
B-cv-bin-percent	1674	1675	1
I-cv-bin-percent	1675	1676	%
O	1677	1679	in
O	1680	1684	both
O	1685	1694	treatment
O	1695	1699	arms
O	1699	1700	,
O	1701	1713	respectively
O	1713	1714	.

O	1715	1718	The
O	1719	1722	PLD
O	1722	1723	-
O	1723	1732	docetaxel
O	1733	1744	combination
O	1745	1748	was
O	1749	1753	more
O	1754	1763	effective
O	1764	1768	than
O	1769	1778	docetaxel
O	1779	1784	alone
O	1785	1787	in
O	1788	1793	women
O	1794	1798	with
O	1799	1809	metastatic
O	1810	1816	breast
O	1817	1823	cancer
O	1824	1827	who
O	1828	1831	had
O	1832	1843	experienced
O	1844	1851	relapse
O	1852	1854	at
O	1855	1860	least
O	1861	1862	1
O	1863	1867	year
O	1868	1873	after
O	1874	1879	prior
O	1880	1888	adjuvant
O	1889	1902	anthracycline
O	1903	1910	therapy
O	1911	1918	without
O	1919	1921	an
O	1922	1930	increase
O	1931	1933	in
O	1934	1941	cardiac
O	1942	1950	toxicity
O	1950	1951	,
O	1952	1960	although
O	1961	1974	mucocutaneous
O	1975	1983	toxicity
O	1984	1987	was
O	1988	1992	more
O	1993	1999	common
O	1999	2000	.
